CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

(2015) J. Tabernero et al.   ONCOLOGIST

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy

(2012) Todd M. Bauer et al.   CANCER

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Current Treatment Options for Pancreatic Carcinoma

(2011) Emily Castellanos et al.   Current Oncology Reports

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

(2009) Michele Reni et al.   CANCER

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

(2008) Viviane Hess et al.   LANCET ONCOLOGY